A Phase 4 interventional study of Donepezil Hydrochloride and Placebo in Memory Loss, sponsored by Eisai Inc.. Completed at 54 sites in United States. Open to participants aged 45 Years to 90 Years. Per ClinicalTrials.gov, last updated 2011-04-01.
Sponsored by Eisai Inc. · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 225 studies in Memory Disorders with a site in United States — 35 open to participants now, 51 under way, none of them phase 3. Memory Disorders · United States.
Among the 225 studies in Memory Disorders with a site in United States, this one is the 3rd largest by enrollment of the 187 interventional ones that give a count, is one of 5 that started in 2003, is one of 10 in phase 4, and was the 26th registered.
374 studies on the registry are indexed under Memory Disorders; 68 are open to participants now.
Browse Memory Disorders studies →35 of the 225 studies in Memory Disorders with a site in United States are open now. Recruiting first, the newest first:
The Cleveland Clinic · Sites in United States
Ages 18+
BrainHealth Solutions, Inc. · Sites in United States
Ages 65+
University of Texas at Austin · Sites in United States
Ages 18–90 · Healthy volunteers
Medical University of South Carolina · Sites in United States
Ages 60–85
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 54 Memory Disorders studies recruiting now, 27 (50%) set no upper age limit and 13 (24%) stop at 75 or younger; 3 take children under 18; 22 take healthy volunteers.
This study: 45 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
225 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 34 · Phase 3 13 · Phase 4 10
First in 1995; this study’s year is marked. 5 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 821 is above the median of 71 across 299 interventional studies indexed under Memory Disorders.
Median enrollment 68 across the 187 interventional studies, 197 across the 33 observational. Of the 160 that completed or were terminated, 49 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 225 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
Eisai Co., Ltd. has 2 studies filed under Memory Disorders — fewer than ten, so there is no comparison to draw.
16 of the studies in Memory Disorders with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06391489Dartmouth-Hitchcock Medical CenterHOBSCOTCH for People With Post Acute COVID-19 Syndrome (PACS) | 2026-12 |
| NCT03896529Georgia Institute of TechnologyNeurobiological Mechanisms of Aging and Stress on Prospective Navigation | 2026-12-25 |
| NCT05027789University of California, DavisBrain Boosters 2 in Persons at Risk for Alzheimer's Disease: a Digital Application Supported Intervention | 2026-12-31 |
| NCT05611918Johns Hopkins UniversityREpeated ASSEssment of SurvivorS in Intracerebral Hemorrhage Study | 2026-12-31 |
| NCT05661084Hebrew SeniorLifeNon-invasive Brain Stimulation for Cognitive and Motor Dysfunction in Dementia | 2026-12-31 |
Add all 16 to your calendar (.ics) → With an account.
Among the 225 studies in Memory Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To investigate the efficacy and safety of donepezil in individuals with mild cognitive impairment on measures of cognition, global function and behavior.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Donepezil Hydrochloride
Drug: Placebo
Subects will receive a starting dose of 5 mg orally. Dose-escalation from 5 mg to 10 mg will occur at the Week 9 Visit.
Subjects will receive matching placebo tablets.
Assessment of cognitive and global function in subjects with MCI.
Behavioral, global and cognitive outcomes; Neuroimaging
The record gives a start of Dec 2003, a primary completion of Mar 2007 and a completion of Mar 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Donepezil